These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 26416247

  • 1. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
    Michelotti G, Jiang X, Sosa JA, Diehl AM, Henderson BB.
    Oncotarget; 2015 Oct 27; 6(33):34549-60. PubMed ID: 26416247
    [Abstract] [Full Text] [Related]

  • 2. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW, Kim YH, Lee J, Soh EY, Park TJ, Kim JH.
    Hum Pathol; 2015 Oct 27; 46(10):1557-65. PubMed ID: 26297257
    [Abstract] [Full Text] [Related]

  • 3. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T, Bartolome A, Šelemetjev S, Đorić I, Tatić S, Živaljević V, Cvejić D.
    Exp Mol Pathol; 2018 Oct 27; 105(2):181-189. PubMed ID: 30077672
    [Abstract] [Full Text] [Related]

  • 4. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway.
    Zhou Z, Liu Y, Ma M, Chang L.
    Biomed Pharmacother; 2017 Dec 27; 96():98-103. PubMed ID: 28965013
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling.
    Cho SW, Kim YA, Sun HJ, Ahn HY, Lee EK, Yi KH, Oh BC, Park DJ, Cho BY, Park YJ.
    J Clin Endocrinol Metab; 2014 Sep 27; 99(9):E1641-9. PubMed ID: 24848709
    [Abstract] [Full Text] [Related]

  • 6. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
    Ma J, Huang X, Li Z, Shen Y, Lai J, Su Q, Zhao J, Xu J.
    J Cell Physiol; 2019 Aug 27; 234(10):17739-17748. PubMed ID: 30793770
    [Abstract] [Full Text] [Related]

  • 7. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway.
    Ding S, Qu W, Jiao Y, Zhang J, Zhang C, Dang S.
    Cancer Biomark; 2018 Aug 27; 22(2):217-226. PubMed ID: 29630517
    [Abstract] [Full Text] [Related]

  • 8. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β-catenin signaling.
    Zhang X, Li M, Zuo K, Li D, Ye M, Ding L, Cai H, Fu D, Fan Y, Lv Z.
    J Clin Endocrinol Metab; 2013 Aug 27; 98(8):E1305-13. PubMed ID: 23796566
    [Abstract] [Full Text] [Related]

  • 9. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.
    Wen D, Liao T, Ma B, Qu N, Shi RL, Lu ZW, Wang YL, Wei WJ, Ji QH.
    Cancer Med; 2018 Feb 27; 7(2):285-296. PubMed ID: 29341469
    [Abstract] [Full Text] [Related]

  • 10. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A, Boskovic S, Paunovic I, Bozic V, Cvejic D.
    APMIS; 2016 Apr 27; 124(4):271-7. PubMed ID: 26750533
    [Abstract] [Full Text] [Related]

  • 11. Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation.
    Cho NL, Lin CI, Whang EE, Carothers AM, Moore FD, Ruan DT.
    Thyroid; 2010 Jun 27; 20(6):615-22. PubMed ID: 20470206
    [Abstract] [Full Text] [Related]

  • 12. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.
    Li JY, Han C, Zheng LL, Guo MZ.
    Chin Med J (Engl); 2012 Oct 27; 125(19):3526-31. PubMed ID: 23044318
    [Abstract] [Full Text] [Related]

  • 13. Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma.
    Pyo JS, Kang G, Kim DH, Chae SW, Park C, Kim K, Do SI, Lee HJ, Kim JH, Sohn JH.
    Pathol Res Pract; 2013 Apr 27; 209(4):228-32. PubMed ID: 23528368
    [Abstract] [Full Text] [Related]

  • 14. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T, Shen X, Liu R, Zhu G, Bishop J, Xing M.
    Oncotarget; 2017 Jan 03; 8(1):900-914. PubMed ID: 27863429
    [Abstract] [Full Text] [Related]

  • 15. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S, Go C, Aniss A, Sidhu S, Delbridge L, Learoyd D, Clifton-Bligh R, Tacon L, Tsang V, Robinson B, Gill AJ, Sywak M.
    World J Surg; 2016 Jul 03; 40(7):1618-24. PubMed ID: 27138882
    [Abstract] [Full Text] [Related]

  • 16. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY, Yoo JH, Park ES, Kim MK, Lee TJ, Cho BY, Chung YJ, Kang KH, Ahn HY, Kim HS.
    Pathol Res Pract; 2015 Feb 03; 211(2):162-70. PubMed ID: 25468810
    [Abstract] [Full Text] [Related]

  • 17. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA.
    JAMA Otolaryngol Head Neck Surg; 2013 Nov 03; 139(11):1164-70. PubMed ID: 24030686
    [Abstract] [Full Text] [Related]

  • 18. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
    Shi C, Qin H, Ding C, Sun Y, Lyu Y, Shi T.
    Zhonghua Zhong Liu Za Zhi; 2015 Feb 03; 37(2):123-7. PubMed ID: 25975689
    [Abstract] [Full Text] [Related]

  • 19. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
    Yin DT, Xu J, Lei M, Li H, Wang Y, Liu Z, Zhou Y, Xing M.
    Oncotarget; 2016 Feb 02; 7(5):5830-41. PubMed ID: 26716505
    [Abstract] [Full Text] [Related]

  • 20. Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.
    Zhao Z, Herman JG, Brock MV, Sheng J, Zhang M, Liu B, Guo M.
    PLoS One; 2014 Feb 02; 9(11):e112336. PubMed ID: 25375359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.